Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | MC4R | P32245 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698518 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL7566114 | 0.83 | PTGS2 (0.86) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL13659050 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL8770202 | 0.80 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL1687503 | 0.80 | PTGS2 (0.79) | PTGS2PTGS1 | |
| Rofecoxib SCHEMBL14163950 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL3050 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL5858026 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL4434618 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL28332047 | 0.80 | PTGS2 (0.54) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236455-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. (US) | 2021-08-05 | — | — | US | disclosed |
| CN-107630001-A | Strengthen the material and method of candidate stem cell implantation process | 印第安纳大学研究与技术公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107523587-A | Strengthen the material and method of candidate stem cell implantation process | 印第安纳大学研究与技术公司 | 2017-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236455-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | PTGS2 764/4885PTGS1 581/4885ABCB11 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.